On this news, the price of Hims' shares fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume. The first-filed case is Sookdeo v. Hims & Hers Health, ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $50.46, demonstrating a -3.02% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered ...

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

In July 2025, the U.S. markets have been experiencing mixed movements as inflation data and earnings reports from major financial institutions influence investor sentiment. Despite these fluctuations, ...

The First Trust Mid Cap Growth AlphaDEX ETF (FNY) made its debut on 04/19/2011, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Mid Cap Growth category of the ...

SO Britain’s second-least worst prince is on manoeuvres. Prince Andrew’s nephew, Harry, has been quietly negotiating behind ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...